Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.6 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients

December 3, 2014
RAMSEY, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and…

Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer

November 17, 2014
DUBLIN, Nov. 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (NASDAQ:…

ViewRay MRIdian System Receives CE Mark

November 12, 2014
CLEVELAND, Ohio, November 11, 2014— ViewRay™, a privately held medical device company, announced today that its MRIdian™ \mə-ˈri-dē-ən\ system, the world’s first and only MRI-guided radiation therapy system, has received…